BioLineRx to Report Second Quarter 2024 Results on August 15, 2024

Rhea-AI Summary

BioLineRx (NASDAQ: BLRX), a commercial stage biopharmaceutical company focusing on oncology and rare diseases, will announce its second quarter 2024 financial results on August 15, 2024, before the U.S. markets open.

The company will host a conference call at 8:30 a.m. EDT on the same day, featuring remarks by CEO Philip Serlin. Investors can join the call by dialing +1-888-281-1167 (U.S.) or +972-3-918-0685 (international).

A live webcast and replay of the call will be available on the company's website. The replay can also be accessed by dialing +1-888-295-2634 (U.S.) or +972-3-925-5904 (international) until August 19, 2024.

Management to Hold Conference Call at 8:30 a.m. EDT

TEL AVIV, Israel, Aug. 8, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its unaudited financial results for the second quarter ended June 30, 2024 on Thursday, August 15, 2024, before the U.S. markets open.

The Company will host a conference call at 8:30 a.m. EDT featuring remarks by Philip Serlin, Chief Executive Officer.

To access the conference call, please dial +1-888-281-1167 from the U.S. or +972-3-918-0685 internationally. A live webcast and a replay of the call can be accessed through the event page on the Company's website. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast. The call replay will be available approximately two hours after completion of the live conference call. A dial-in replay of the call will be available until August 19, 2024; please dial +1-888-295-2634 from the US or +972-3-925-5904 internationally.

About BioLineRx

BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The company's first approved product is APHEXDA® (motixafortide) with an indication in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma. BioLineRx is advancing a pipeline of investigational medicines for patients with sickle cell disease, pancreatic cancer, and other solid tumors. Headquartered in Israel, and with operations in the U.S., the company is driving innovative therapeutics with end-to-end expertise in development and commercialization, ensuring life-changing discoveries move beyond the bench to the bedside.

Learn more about who we are, what we do, and how we do it at www.biolinerx.com, or on Twitter and LinkedIn.  and events.

CONTACTS:

United States
John Lacey
BioLineRx
IR@biolinerx.com

Israel
Moran Meir
LifeSci Advisors, LLC
moran@lifesciadvisors.com

Logo: https://mma.prnewswire.com/media/2154863/4547338/BioLineRx_Ltd_Logo.jpg

 

View original content:https://www.prnewswire.com/news-releases/biolinerx-to-report-second-quarter-2024-results-on-august-15-2024-302217780.html

SOURCE BioLineRx Ltd.

FAQ

When will BioLineRx report its second quarter 2024 results?

BioLineRx will report its second quarter 2024 results on August 15, 2024.

What time is BioLineRx's Q2 2024 earnings conference call?

BioLineRx's Q2 2024 earnings conference call will be held at 8:30 a.m. EDT on August 15, 2024.

How can I join BioLineRx's Q2 2024 earnings call?

You can join BioLineRx's Q2 2024 earnings call by dialing +1-888-281-1167 (U.S.) or +972-3-918-0685 (international).

Will there be a replay available for BioLineRx's Q2 2024 earnings call?

Yes, a replay of BioLineRx's Q2 2024 earnings call will be available on the company's website and by dialing +1-888-295-2634 (U.S.) or +972-3-925-5904 (international) until August 19, 2024.